Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAESAR
2022-502155-65-00Phase 3Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sarcoidosis comparing Hydroxychloroquine + prednisone with Placebo + prednisone (2 arms). Planned start Apr 2023; status: authorised.
02
Drugs
hydroxychloroquine
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on 2022-502155-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502155-65-00.